216 related articles for article (PubMed ID: 24233486)
1. Translation of human tissue factor pathway inhibitor-β mRNA is controlled by alternative splicing within the 5' untranslated region.
Ellery PE; Maroney SA; Martinez ND; Wickens MP; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):187-95. PubMed ID: 24233486
[TBL] [Abstract][Full Text] [Related]
2. Biology of tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Blood; 2014 May; 123(19):2934-43. PubMed ID: 24620349
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans.
Maroney SA; Ferrel JP; Collins ML; Mast AE
J Thromb Haemost; 2008 Aug; 6(8):1344-51. PubMed ID: 18503630
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ.
Maroney SA; Ellery PE; Wood JP; Ferrel JP; Martinez ND; Mast AE
J Thromb Haemost; 2013 May; 11(5):911-8. PubMed ID: 23480518
[TBL] [Abstract][Full Text] [Related]
5. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cell-surface TFPIalpha and beta.
Piro O; Broze GJ
J Thromb Haemost; 2005 Dec; 3(12):2677-83. PubMed ID: 16246254
[TBL] [Abstract][Full Text] [Related]
7. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.
Stavik B; Tinholt M; Sletten M; Skretting G; Sandset PM; Iversen N
J Hematol Oncol; 2013 Jan; 6():5. PubMed ID: 23320987
[TBL] [Abstract][Full Text] [Related]
8. Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.
Maroney SA; Ferrel JP; Pan S; White TA; Simari RD; McVey JH; Mast AE
J Thromb Haemost; 2009 Jul; 7(7):1106-13. PubMed ID: 19422457
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.
Girard TJ; Grunz K; Lasky NM; Malone JP; Broze GJ
J Thromb Haemost; 2018 Nov; 16(11):2246-2257. PubMed ID: 30194803
[TBL] [Abstract][Full Text] [Related]
10. New insights into the biology of tissue factor pathway inhibitor.
Maroney SA; Mast AE
J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S200-7. PubMed ID: 26149025
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
Wood JP; Bunce MW; Maroney SA; Tracy PB; Camire RM; Mast AE
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17838-43. PubMed ID: 24127605
[TBL] [Abstract][Full Text] [Related]
12. Translational regulation of human neuronal nitric-oxide synthase by an alternatively spliced 5'-untranslated region leader exon.
Newton DC; Bevan SC; Choi S; Robb GB; Millar A; Wang Y; Marsden PA
J Biol Chem; 2003 Jan; 278(1):636-44. PubMed ID: 12403769
[TBL] [Abstract][Full Text] [Related]
13. TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes.
Girard TJ; Tuley E; Broze GJ
Blood; 2012 Feb; 119(5):1256-62. PubMed ID: 22144186
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.
Tinholt M; Stavik B; Louch W; Carlson CR; Sletten M; Ruf W; Skretting G; Sandset PM; Iversen N
PLoS One; 2015; 10(1):e0117404. PubMed ID: 25617766
[TBL] [Abstract][Full Text] [Related]
15. Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor.
Maroney SA; Hansen KG; Mast AE
Curr Opin Hematol; 2013 Sep; 20(5):403-9. PubMed ID: 23839295
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of two novel 5' untranslated exons reveals a complex regulation of NOD2 protein expression.
Rosenstiel P; Huse K; Franke A; Hampe J; Reichwald K; Platzer C; Roberts RG; Mathew CG; Platzer M; Schreiber S
BMC Genomics; 2007 Dec; 8():472. PubMed ID: 18096043
[TBL] [Abstract][Full Text] [Related]
17. The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor α.
Ali HO; Arroyo AB; González-Conejero R; Stavik B; Iversen N; Sandset PM; Martínez C; Skretting G
J Thromb Haemost; 2016 Jun; 14(6):1226-37. PubMed ID: 26999003
[TBL] [Abstract][Full Text] [Related]
18. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
19. Alternatively spliced isoforms of tissue factor pathway inhibitor.
Maroney SA; Ellery PE; Mast AE
Thromb Res; 2010 Apr; 125 Suppl 1():S52-6. PubMed ID: 20176395
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor: structure-function.
Broze GJ; Girard TJ
Front Biosci (Landmark Ed); 2012 Jan; 17(1):262-80. PubMed ID: 22201743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
